WCG
PFE icon

Weaver Consulting Group’s Pfizer PFE Stock Holding History

Weaver Consulting Group’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$335K Sell
11,741
-232
-2% -$6.17K 0.07% 221
2026
Q2 		$288K Buy
11,973
+540
+5% +$14.1K 0.06% 235
2026
Q1 		$321K Buy
11,433
+244
+2% +$6.5K 0.08% 190
2025
Q4 		$279K Buy
11,189
+1,652
+17% +$41.7K 0.07% 213
2025
Q3 		$243K Sell
9,537
-620
-6% -$15.3K 0.06% 229
2025
Q2 		$246K Sell
10,157
-210
-2% -$4.9K 0.07% 207
2025
Q1 		$263K Sell
10,367
-308
-3% -$8.06K 0.08% 190
2024
Q4 		$283K Sell
10,675
-2,638
-20% -$71.6K 0.09% 167
2024
Q3 		$385K Buy
13,313
+65
+0.5% +$1.9K 0.12% 136
2024
Q2 		$371K Buy
13,248
+226
+2% +$6.22K 0.13% 131
2024
Q1 		$361K Buy
13,022
+2,980
+30% +$82.7K 0.13% 137
2023
Q4 		$289K Buy
+10,042
New +$304K 0.12% 149
2023
Q2 		– Sell
-5,179
Closed -$211K – 190
2023
Q1 		$211K Sell
5,179
-397
-7% -$17.1K 0.1% 168
2022
Q4 		$286K Buy
5,576
+18
+0.3% +$863 0.15% 134
2022
Q3 		$243K Sell
5,558
-80
-1% -$3.89K 0.14% 137
2022
Q2 		$296K Sell
5,638
-115
-2% -$5.86K 0.17% 124
2022
Q1 		$298K Sell
5,753
-396
-6% -$20.5K 0.14% 132
2021
Q4 		$363K Sell
6,149
-50
-0.8% -$2.48K 0.17% 110
2021
Q3 		$267K Buy
6,199
+56
+0.9% +$2.48K 0.15% 123
2021
Q2 		$241K Sell
6,143
-221
-3% -$8.59K 0.14% 126
2021
Q1 		$231K Buy
6,364
+573
+10% +$20.3K 0.14% 123
2020
Q4 		$213K Sell
5,791
-17
-0.3% -$624 0.13% 128
2020
Q3 		$202K Hold
5,808
– – 0.12% 120
2020
Q2 		$180K Buy
5,808
+318
+6% +$10.8K 0.1% 137
2020
Q1 		$170K Sell
5,490
-1,663
-23% -$56.7K 0.11% 118
2019
Q4 		$244K Buy
7,153
+2,338
+49% +$83.3K 0.13% 99
2019
Q3 		$177K Buy
4,815
+844
+21% +$30.7K 0.09% 115
2019
Q2 		$163K Hold
3,971
– – 0.09% 113
2019
Q1 		$162K Buy
+3,971
New +$159K 0.05% 243

Other funds holding PFE

AIM
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
MSV
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
VWM
Valley Wealth Managers Paramus, New Jersey $1.76B AUM 33.82% 1-Year Est. Return
SIS
Sound Income Strategies Ft Lauderdale, Florida $2.24B AUM 8.38% 1-Year Est. Return
QPBE
Quintet Private Bank (Europe) Luxembourg $2.28B AUM 23.89% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
RT
Rockland Trust Hanover, Massachusetts $2.61B AUM 14.26% 1-Year Est. Return
WF
WoodTrust Financial Wisconsin Rapids, Wisconsin $825M AUM 20.13% 1-Year Est. Return
AAA
Adams Asset Advisors Dallas, Texas $984M AUM 41.12% 1-Year Est. Return
ACM
Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return

Weaver Consulting Group's PFE Position: Q3 2026 in Review

Weaver Consulting Group reduced its Pfizer (PFE) stake by 1.9% in Q3 2026, selling an estimated $6.17K and leaving 11,741 shares worth $335K. The position accounts for 0.07% of the portfolio, ranked #221.

Weaver Consulting Group first reported a position in PFE in Q1 2019 and has held it in 29 quarters since. The position peaked at $385K in Q3 2024. 156 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Weaver Consulting Group held 11,741 shares of Pfizer worth $335K as of Q3 2026.
  • Weaver Consulting Group sold 232 Pfizer shares in Q3 2026, an estimated $6.17K.
  • Pfizer made up 0.07% of Weaver Consulting Group's portfolio in Q3 2026, its #221 holding.
  • Weaver Consulting Group first reported a position in Pfizer in Q1 2019 and has held it in 29 quarters since.
  • Weaver Consulting Group's Pfizer position peaked at $385K in Q3 2024.
  • 156 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Weaver Consulting Group's 13F filing for Q3 2026, filed 7 Oct 2026.